Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019246520 - AMINOBISPHOSPHONATES AS LATENCY REVERSING AGENTS AND COMBINATION TREATMENTS FOR HIV CURE

Publication Number WO/2019/246520
Publication Date 26.12.2019
International Application No. PCT/US2019/038469
International Filing Date 21.06.2019
IPC
A61K 31/663 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
662Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 31/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
CPC
A61K 31/167
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/663
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
Applicants
  • THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US]/[US]
Inventors
  • SORIANO-SARABIA, Natalia
Agents
  • LETTS, Nathan, P.
Priority Data
62/687,93621.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AMINOBISPHOSPHONATES AS LATENCY REVERSING AGENTS AND COMBINATION TREATMENTS FOR HIV CURE
(FR) AMINOBISPHOSPHONATES COMME AGENTS D’INVERSION DE LATENCE ET TRAITEMENTS COMBINÉS POUR LE TRAITEMENT DU VIH
Abstract
(EN)
The present disclosure provides novel methods to cure HIV. In particular aminobisphosphonates are disclosed as latency reversing agents (LRAs), and methods to cure HIV by administering to a subject a combination of bisphosphonates and γδ T cells are provided. In some embodiments, these interventions may be combined with other latency reversing agents, e.g., histone deacetylase (HD AC) inhibitors, and other immunotherapeutics for HIV clearance (e.g., broadly HIV -neutralizing antibodies).
(FR)
La présente invention concerne de nouveaux procédés de traitement du VIH. En particulier, la présente invention concerne des aminobisphosphonates comme agents d’inversion de latence (LRA), et des procédés de traitement du VIH par administration à un sujet d’une combinaison de bisphosphonates et de cellules T γδ. Dans certains modes de réalisation, ces interventions peuvent être associées à d’autres agents d’inversion de latence, par exemple, des inhibiteurs de désacétylases d'histones (HD AC), et d’autres agents immunothérapeutiques d’élimination du VIH (par exemple, généralement des anticorps de neutralisation du VIH).
Latest bibliographic data on file with the International Bureau